Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SCB-2019 vaccine immunogenicity and safety study in healthy adults and adults with HIV infection
PACTR202108616900606Phase 3Not yet recruiting
- Sponsor
- Clover Biopharmaceuticals
- Start
- Aug 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing SCB-2019 vaccine with Placebo (2 arms). Primary endpoint: SARS-CoV-2 neutralizing antibody titers 21 days after second vaccination. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202108616900606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202108616900606.